Abstract
Pharmaceutical executives with varying backgrounds and expertise are increasingly being asked to provide input on complex strategies related to portfolios of products, including regulatory and commercial competitive intelligence. Given the appropriate expertise – including preclinical, clinical pharmacology, clinical, regulatory affairs, CMC (Chemistry, Manufacturing and Controls)/supply chain, commercial, and patent law – they may be asked to help estimate the probabilities of achieving clinical milestones such as regulatory approval in a market of interest. They may also be asked to comment on product development even earlier in the development cycle, taking into account commercial insights, payer perspectives and quality-of-life issues. This chapter discusses investment decisions based on the author’s experience in investing in portfolios of pharmaceutical products, such as how much one can invest, and the palatability of the proposed return structure. The chapter breaks down many facets of this complex process to give insights into business decisions related to portfolios. Differences in portfolio strategy between big pharma and biotech companies are discussed, along with portfolio management, innovative partnering strategies and commercial perspectives
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.